PETAL Consortium study on T-cell and NK-cell lymphoma
Part of Cancer clinical trials.
This study, run by Massachusetts General Hospital, is collecting information from people around the world who have certain types of T-cell or NK-cell lymphoma. It aims to learn more about these cancers and how they are managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a mature T-cell or NK-cell lymphoma (a type of blood cancer).
- Your lymphoma can be untreated, or it may have come back after treatment (relapsed) or not responded to treatment (refractory).
- You cannot have certain other types of T-cell lymphoma, such as T-cell large granular lymphocytic leukemia, mycosis fungoides, Sézary syndrome, or primary cutaneous CD30+ disorders.
- You must be an adult able to give your own consent, and not pregnant or a prisoner.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This study is looking at people with peripheral T-cell lymphoma, a type of blood cancer. It will use genetic testing to understand different subtypes of the cancer and how they affect patients' outcomes.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new T-Cell and NK-Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.